The reimbursement conditions for 6 specific types of antiviral hepatitis C medication for the treatment of chronic hepatitis C patients will be extended and 2 new ones will be added. This extended reimbursement will be active starting from 1.1.2017 and is agreed upon for a period of 2 years between RIZIV-INAMI and the 5 involved pharmaceutical companies via a contract of type Art.81 signed with the RIZIV-INAMI..
The hepatitis C antiviral medication is on the list of Chapter 4 medication, which requires the treating physician to fill out a dedicated form to apply for reimbursement. Apart from this information, the treating physician is also obliged to participate in the registration of follow-up data of his/her patients using this antiviral hepatitis C medication.
 The 8 pharmaceuticals involved are HARVONI, EXVIERA, VIEKIRAX, DAKLINZA, OLYSIO, SOVALDI, EPCLUSA (new) and ZEPATIER (new).
Data and Resources
|Release Date|| |
|Public Access Level|| |